Siroy Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-06-2024
- Paid Up Capital ₹ 1.00 M
as on 27-06-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2017)
- Profit 67.74%
(FY 2017)
- Ebitda -538.46%
(FY 2017)
- Net Worth -4.70%
(FY 2017)
- Total Assets 94.89%
(FY 2017)
About Siroy Life Sciences
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Hijam Singha, Brajesh Bauddh, Hijam Gouri, and One other member serve as directors at the Company.
- CIN/LLPIN
U33110DL2015PTC280472
- Company No.
280472
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 May 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Siroy Life Sciences Private Limited offer?
Siroy Life Sciences Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Skin Care Cosmetics, Common Disease Medicines, Pharmaceutical Capsules, Floor Cleaner, Liquid Floor Cleaner, Face Cream, Fairness Cream, Mineral Supplement, Calcium Supplements.
Who are the key members and board of directors at Siroy Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hijam Singha  | Director | 20-May-2015 | Current |
| Brajesh Bauddh | Director | 18-Mar-2016 | Current |
| Hijam Gouri | Director | 20-May-2015 | Current |
| Vijay Kumar | Director | 21-Apr-2016 | Current |
Financial Performance of Siroy Life Sciences.
Siroy Life Sciences Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 67.74% increase in profit. The company's net worth dipped by a decrease of 4.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Siroy Life Sciences?
In 2017, Siroy Life Sciences had a promoter holding of 35.00% and a public holding of 65.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Siroy Life Sciences?
Unlock and access historical data on people associated with Siroy Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Siroy Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Siroy Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
